INZY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
INZY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Inozyme Pharma's quarterly gross PPE declined from Mar. 2024 ($2.31 Mil) to Jun. 2024 ($1.98 Mil) and declined from Jun. 2024 ($1.98 Mil) to Sep. 2024 ($1.66 Mil).
Inozyme Pharma's annual gross PPE stayed the same from Dec. 2021 ($5.44 Mil) to Dec. 2022 ($5.37 Mil) but then declined from Dec. 2022 ($5.37 Mil) to Dec. 2023 ($5.01 Mil).
The historical data trend for Inozyme Pharma's Gross Property, Plant and Equipment can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inozyme Pharma Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Gross Property, Plant and Equipment | Get a 7-Day Free Trial | 0.41 | 2.98 | 5.44 | 5.37 | 5.01 |
Inozyme Pharma Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Gross Property, Plant and Equipment | Get a 7-Day Free Trial | 2.84 | 5.01 | 2.31 | 1.98 | 1.66 |
Property, Plant and Equipment (PPE) are the fixed assets of the company. Fixed assets are also known as non-current assets.
Property, plant, and equipment includes assets that will - in the normal course of business - neither be used up in the next year nor will become a part of any product sold to customers.
Some of the most common parts of property, plant, and equipment are:
Companies with lots of property, plant, and equipment often have special categories. For example, railroad property includes:
There is often a note in the financial statements - found in a company's 10-K - that will explain the different categories of property a company owns.
The market value of property, plant, and equipment can differ tremendously from the book value of property, plant, and equipment.
For example, when Berkshire Hathaway liquidated its textile mills, it had to pay the buyers of the company's manufacturing equipment to haul the equipment away. That property, plant, and equipment was literally worth less than zero. On the other hand, some companies own thousands of acres of land.
All property, plant, and equipment other than land is depreciated. Land is never depreciated. However, land is not marked up to market value either. Under Generally Accepted Accounting Principles (GAAP), land is shown on the balance sheet at cost.
The property, plant, and equipment line shown on the balance sheet is usually net property, plant, and equipment. This means it is the cost of the property, plant, and equipment less accumulated depreciation.
Inozyme Pharma (NAS:INZY) Gross Property, Plant and Equipment Explanation
A company with durable competitive advantage doesn't need to constantly upgrade its equipment to stay competitive. The company replaces when it wears out. On the other hand, a company without any advantages must replace to keep pace.
Difference between a company with a moat and one without is that the company with the competitive advantage finances new equipment through internal cash flows, whereas the no advantage company requires debt to finance.
Producing a consistent product that doesn't change equates to consistent profits. There is no need to upgrade plants which frees up cash for other ventures. Think Coca Cola, Johnson & Johnson etc.
Thank you for viewing the detailed overview of Inozyme Pharma's Gross Property, Plant and Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.
Douglas A Treco | director | 87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140 |
Robert Lorne Hopfner | director, 10 percent owner | C/O BAY CITY CAPITAL, LLC, 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111 |
Pivotal Bioventure Partners Fund I G.p., L.p. | director | 501 SECOND STREET, SUITE 200, SAN FRANCISCO CA 94107 |
Pivotal Bioventure Partners Fund I U.g.p. Ltd | director | 501 SECOND STREET, SUITE 200, SAN FRANCISCO CA 94107 |
Pivotal Bioventure Partners Fund I, L.p. | director | 501 SECOND STREET, SUITE 200, SAN FRANCISCO CA 94107 |
Matthew Winton | officer: COO | C/O INOZYME PHARMA, INC., 321 SUMMER STREET, SUITE 400, BOSTON MA 02210 |
Sanjay Subramanian | officer: SVP, CFO | 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355 |
Henric Bjorn Bjarke | officer: See Remarks | ONE UNIVERSITY SQUARE DRIVE, SUITE 280, PRINCETON NJ 08540 |
Axel Bolte | director, 10 percent owner, officer: See Remarks | PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080 |
Longitude Capital Partners Iii, Llc | 10 percent owner | 800 EL CAMINO, SUITE 220, MENLO PARK CA 94025 |
Inozyme Pharma, Inc. | director | 321 SUMMER STREET, SUITE 400, BOSTON MA 02210 |
Stephen J. Dipalma | officer: Interim CFO | C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139 |
Deborah Wenkert | officer: SVP, CMO | C/O INOZYME PHARMA, INC., 321 SUMMER STREET, SUITE 400, BOSTON MA 02210 |
Novo Holdings A/s | 10 percent owner | TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
Scott D Sandell | 10 percent owner |
From GuruFocus
By GuruFocus Research • 02-07-2024
By Marketwired • 10-17-2024
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
By Marketwired • 08-29-2024
By Marketwired • 05-03-2024
By Marketwired • 11-03-2023
By Marketwired • 10-07-2024
By GuruFocus News • 11-14-2024
By GuruFocus Research • 02-07-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.